Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
AVEM vs IBB: how they differ
AVEM and IBB hold 0% of their weight in the same names, and IBB returned more over the year.
Avantis Emerging Markets Equity ETF and iShares Biotechnology ETF.
What they hold in common
By the books each fund has filed, AVEM and IBB hold 0% of their money in the same securities at the same weight.
| Holding | AVEM | IBB |
|---|---|---|
| BeOne Medicines Ltd | 0.01% | 1.77% |
| Only in AVEM | Only in IBB |
|---|---|
| SK hynix Inc 7.83% | Vertex Pharmaceuticals, Inc. 8.09% |
| Taiwan Semiconductor Manufacturing Co Lt 6.33% | Amgen, Inc. 7.84% |
| Samsung Electronics Co Ltd 5.70% | Gilead Sciences, Inc. 6.85% |
| Taiwan Semiconductor Manufacturing Co Lt 4.11% | Regeneron Pharmaceuticals, Inc. 4.91% |
| Tencent Holdings Ltd 1.51% | Argenx SE 3.76% |
| MediaTek Inc 1.11% | Alnylam Pharmaceuticals, Inc. 3.12% |
| China Construction Bank Corp 0.89% | Natera, Inc. 2.89% |
| Alibaba Group Holding Ltd 0.81% | Revolution Medicines, Inc. 2.78% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.
| AVEM Avantis Emerging Markets Equity ETF | IBB iShares Biotechnology ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Avantis | iShares |
| What it is | Emerging Markets Equity | Biotechnology |
| Total return, 1 year | +31.8% | +41.5% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +14.3 pts | +24.0 pts |
| Expense ratio | 0.33% | 0.44% |
| Already in the S&P 500 | 0.0% | 35.6% |
| Holdings | 3897 | 248 |
AVEM in plain words
AVEM is an index equity fund tracking the Emerging Markets Equity. Over the year to Sep 11, 2026 it returned +31.8% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.33% a year. By its holdings filed for May 31, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 3897 positions, with the top ten at 29.9%. It sat 4.2% below its high of Jun 22, 2026 on Sep 11, 2026.
IBB in plain words
IBB is an index equity fund tracking the Biotechnology. Over the year to Sep 11, 2026 it returned +41.5% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.44% a year. By its holdings filed for Jun 30, 2026, 36% of the fund by weight is stocks the S&P 500 also holds, across 248 positions, with the top ten at 44.8%. It sat 6.5% below its high of Aug 19, 2026 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, AVEM or IBB?
- In the year to Sep 12, 2026, with distributions reinvested, AVEM returned +31.8% and IBB returned +41.5%, so IBB returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, AVEM or IBB?
- AVEM charges 0.33% a year and IBB charges 0.44%, so AVEM is cheaper. Fees come from each fund's prospectus.
- How much do AVEM and IBB overlap with the S&P 500?
- By their latest filed holdings, 0% of AVEM and 36% of IBB by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, AVEM against IBB, data as of Sep 12, 2026. https://etfiq.com/compare/any/AVEM-IBB Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources